secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2023-11-03T23:59:59+00:00
Accession:  0001171843-23-006717
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst pipeline update: five programs to enter clinic by 2025, R&D spend guided $230-240M in 2024
--------------------------------------------------------------------------------

- BCX17725 (fusion protein KLK5 inhibitor) for Netherton syndrome entering clinic 2H 2024.
- Avoralstat + Clearside SCS Microinjector for DME to enter clinic in 2025.
- Oral C5 inhibitor for generalized myasthenia gravis to enter clinic in 2025.
- Bifunctional complement inhibitor targeting multiple pathways for IgAN and lupus nephritis to enter clinic in 2025.
- 2024 R&D spending guided at $230-240M, up from projected 2023 spending of $25-35M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184323006717/0001171843-23-006717-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184323006717/f8k_110323.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-006717

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer